Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study

Publisher： Karger

E-ISSN： 1423-0232|92|2|94-100

ISSN： 0030-2414

Source： Oncology, Vol.92, Iss.2, 2016-12, pp. : 94-100

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical benefits of non‐taxane chemotherapies in unselected patients with symptomatic metastatic castration‐resistant prostate cancer after docetaxel: the GETUG‐P02 study

By  

BJU INTERNATIONAL, Vol. 115, Iss. 1, 2015-01 ,pp. : 65-73

John Wiley & Sons Inc

Access to resources Recommend Favorite

Docetaxel rechallenge after an initial good response in patients with metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 115, Iss. 5, 2015-05 ,pp. : 744-752

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cabazitaxel for the therapy of metastatic castration‐resistant prostate cancer in the aftermath of the CHAARTED trial

By  

BJU INTERNATIONAL, Vol. 116, Iss. 6, 2015-12 ,pp. : 839-840

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and efficacy of 2‐weekly cabazitaxel in metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 121, Iss. 2, 2018-02 ,pp. : 203-208

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 968-975

John Wiley & Sons Inc

Access to resources Recommend Favorite